Edgewise Therapeutics Completes Key Phase 2 Trials for EDG-7500

Edgewise Therapeutics shares are trading higher after the company announced the completion of Phase 2 Parts B and C trials for EDG-7500, with favorable interim safety results from the ongoing Part D study in hypertrophic cardiomyopathy.